High dose rate brachytherapy for prostate cancer: Standard of care and future direction.

[1]  Y. Yoshioka,et al.  High-Dose-Rate Brachytherapy as Monotherapy for Intermediate- and High-Risk Prostate Cancer: Clinical Results for a Median 8-Year Follow-Up. , 2016, International journal of radiation oncology, biology, physics.

[2]  M. Steinberg,et al.  High-Dose-Rate Monotherapy for Localized Prostate Cancer: 10-Year Results. , 2016, International journal of radiation oncology, biology, physics.

[3]  Sang-June Park,et al.  Is High-Dose-Rate Monotherapy Suitable for Selected Cases of High-Risk Localized Prostate Cancer? , 2015 .

[4]  J. Aronowitz.  Afterloading: The Technique That Rescued Brachytherapy. , 2015, International journal of radiation oncology, biology, physics.

[5]  Sang-June Park,et al.  From whole gland to hemigland to ultra-focal high-dose-rate prostate brachytherapy: A dosimetric analysis. , 2015, Brachytherapy.

[6]  Hans T. Chung,et al.  High dose-rate brachytherapy boost for intermediate risk prostate cancer: Long-term outcomes of two different treatment schedules and early biochemical predictors of success. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  G. Morton,et al.  High-dose-rate brachytherapy boost for prostate cancer: rationale and technique , 2014, Journal of contemporary brachytherapy.

[8]  A. Padhani,et al.  Optimal source distribution for focal boosts using high dose rate (HDR) brachytherapy alone in prostate cancer. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  Y. Yamada,et al.  Comparison of high‐dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate‐risk prostate cancer , 2014, BJU international.

[10]  M. Milette,et al.  Ultrasound-planned high-dose-rate prostate brachytherapy: dose painting to the dominant intraprostatic lesion. , 2014, Brachytherapy.

[11]  A. Polo,et al.  External beam radiotherapy plus single-fraction high dose rate brachytherapy in the treatment of locally advanced prostate cancer. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  C. Kirisits,et al.  Magnetic resonance image guided brachytherapy. , 2014, Seminars in radiation oncology.

[13]  P. Hoskin,et al.  High-dose-rate brachytherapy with two or three fractions as monotherapy in the treatment of locally advanced prostate cancer. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  E. B. Butler,et al.  Is There an Increase in Genitourinary Toxicity in Patients Treated With Transurethral Resection of the Prostate and Radiotherapy?: A Systematic Review , 2014, American journal of clinical oncology.

[15]  B. Carey,et al.  Multi-parametric MRI-guided focal tumor boost using HDR prostate brachytherapy: a feasibility study. , 2014, Brachytherapy.

[16]  P. Hoskin,et al.  High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: acute toxicity. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  M. Reinfuss,et al.  Salvage prostate HDR brachytherapy combined with interstitial hyperthermia for local recurrence after radiation therapy failure , 2014, Strahlentherapie und Onkologie.

[18]  C. Kirisits,et al.  Review of clinical brachytherapy uncertainties: Analysis guidelines of GEC-ESTRO and the AAPM☆ , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  P. Hoskin,et al.  The influence of prostate volume on outcome after high-dose-rate brachytherapy alone for localized prostate cancer. , 2013, International journal of radiation oncology, biology, physics.

[20]  R. Stock,et al.  The relative importance of hormonal therapy and biological effective dose in optimizing prostate brachytherapy treatment outcomes , 2013, BJU international.

[21]  I. Hsu,et al.  Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. , 2013, International journal of radiation oncology, biology, physics.

[22]  P. Hoskin,et al.  GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  Y. Yamada,et al.  A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy , 2013, Brachytherapy.

[24]  S. van Dyk,et al.  Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer. , 2013, International journal of radiation oncology, biology, physics.

[25]  Dimos Baltas,et al.  High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results. , 2013, International journal of radiation oncology, biology, physics.

[26]  G. Gustafson,et al.  Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer. , 2012, Brachytherapy.

[27]  N. Teixeira,et al.  What do we know about the α/β for prostate cancer? , 2012, Medical physics.

[28]  P. Prada,et al.  Biochemical outcome after high‐dose‐rate intensity modulated brachytherapy with external beam radiotherapy: 12 years of experience , 2012, BJU international.

[29]  P. Hoskin,et al.  Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[30]  G. Gustafson,et al.  High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. , 2011, International journal of radiation oncology, biology, physics.

[31]  H. Sandler,et al.  Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease. , 2011, International journal of radiation oncology, biology, physics.

[32]  D. Kuban,et al.  Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? , 2011, International journal of radiation oncology, biology, physics.

[33]  Liying Zhang,et al.  Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer? , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[34]  R. Miralbell,et al.  High‐dose‐rate brachytherapy boost to the dominant intra‐prostatic tumor region: Hemi‐irradiation of prostate cancer , 2011, The Prostate.

[35]  P. Ágoston,et al.  Moderate dose escalation with single-fraction high-dose-rate brachytherapy boost for clinically localized intermediate- and high-risk prostate cancer: 5-year outcome of the first 100 consecutively treated patients. , 2011, Brachytherapy.

[36]  J. Aronowitz,et al.  Precedence for prostate brachytherapy. , 2011, Brachytherapy.

[37]  B. Carey,et al.  Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. , 2011, European urology.

[38]  J. Pouliot,et al.  Interactive, multi-modality image registrations for combined MRI/MRSI-planned HDR prostate brachytherapy , 2011, Journal of contemporary brachytherapy.

[39]  A. Kułakowski.  The contribution of Marie Skłodowska-Curie to the development of modern oncology , 2011, Analytical and bioanalytical chemistry.

[40]  G. Sasso,et al.  MRS-guided HDR brachytherapy boost to the dominant intraprostatic lesion in high risk localised prostate cancer , 2010, BMC Cancer.

[41]  L. Schour,et al.  Excellent Results From High Dose Rate Brachytherapy and External Beam for Prostate Cancer are Not Improved by Androgen Deprivation , 2009, American journal of clinical oncology.

[42]  G. Gustafson,et al.  Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[43]  Y. Yamada,et al.  Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. , 2008, Brachytherapy.

[44]  A. Peddada,et al.  Low morbidity following high dose rate brachytherapy in the setting of prior transurethral prostate resection. , 2007, The Journal of urology.

[45]  Jeffrey F Williamson,et al.  Brachytherapy technology and physics practice since 1950: a half-century of progress , 2006, Physics in medicine and biology.

[46]  M. Blute,et al.  Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. , 2005, The Journal of urology.

[47]  R. Pötter,et al.  GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[48]  T. Mate,et al.  Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. , 2004, International journal of radiation oncology, biology, physics.

[49]  J. Aronowitz.  Benjamin Barringer: originator of the transperineal prostate implant. , 2002, Urology.

[50]  J. Fowler,et al.  A simple analytic derivation suggests that prostate cancer α/β ratio is low , 2001 .

[51]  A. D'Amico,et al.  Real-time magnetic resonance image-guided interstitial brachytherapy in the treatment of select patients with clinically localized prostate cancer. , 1998, International journal of radiation oncology, biology, physics.

[52]  R. Das,et al.  ICRU 58 (Dose and Volume Specification for Reporting Interstitial Therapy), by International Commission on Radiation Units and Measurements , 1998 .

[53]  G. Gustafson,et al.  Conformal prostate brachytherapy: initial experience of a phase I/II dose-escalating trial. , 1995, International journal of radiation oncology, biology, physics.

[54]  B. S. Barringer.  CARCINOMA OF THE PROSTATE , 1931, Annals of surgery.

[55]  A. D'Amico,et al.  ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer. , 2014, Brachytherapy.

[56]  J. Millar,et al.  Urethral strictures following high-dose-rate brachytherapy for prostate cancer: analysis of risk factors. , 2013, Brachytherapy.

[57]  Y. Yamada,et al.  Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer. , 2013, Brachytherapy.

[58]  R. Hansen,et al.  High dose brachytherapy as monotherapy for intermediate risk prostate cancer. , 2012, The Journal of urology.

[59]  J. Pouliot,et al.  American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. , 2012, Brachytherapy.

[60]  Thomas Wiegel,et al.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. , 2011, European urology.

[61]  A. Peddada,et al.  High-dose-rate brachytherapy for large prostate volumes (> or =50cc)-Uncompromised dosimetric coverage and acceptable toxicity. , 2008, Brachytherapy.

[62]  X. Allen Li,et al.  HOW LOW IS THE / RATIO FOR PROSTATE CANCER? , 2003 .

[63]  R. Abrams,et al.  Acute and late radiotherapy toxicity in patients with inflammatory bowel disease. , 2001, International journal of radiation oncology, biology, physics.